Figure 3.

Treatment period in the three frailty subgroups of patients aged ≥75 years. A total of 19 patients (63.3%), 8 patients (50.0%) and 4 patients (33.3%) in the low-, intermediate- and high-frailty subgroups, respectively, were able to continue programmed cell death protein-1/programmed cell death ligand 1 inhibitor treatment for >6 months. There was no significant difference among the three subgroups (P=0.20). Fisher's exact test was used and Bonferroni adjustment was used for multiple comparisons.